Wellington Management Group LLP Sells 13,834 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Wellington Management Group LLP lessened its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 11.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 105,459 shares of the biotechnology company's stock after selling 13,834 shares during the quarter. Wellington Management Group LLP's holdings in ADMA Biologics were worth $1,809,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of ADMA. KBC Group NV boosted its position in shares of ADMA Biologics by 53.6% in the fourth quarter. KBC Group NV now owns 10,063 shares of the biotechnology company's stock valued at $173,000 after acquiring an additional 3,513 shares during the period. Jennison Associates LLC boosted its position in shares of ADMA Biologics by 29.3% in the fourth quarter. Jennison Associates LLC now owns 44,640 shares of the biotechnology company's stock valued at $766,000 after acquiring an additional 10,125 shares during the period. Bleakley Financial Group LLC boosted its position in shares of ADMA Biologics by 63.5% in the fourth quarter. Bleakley Financial Group LLC now owns 16,739 shares of the biotechnology company's stock valued at $287,000 after acquiring an additional 6,498 shares during the period. State of Alaska Department of Revenue boosted its position in shares of ADMA Biologics by 1.0% in the fourth quarter. State of Alaska Department of Revenue now owns 134,346 shares of the biotechnology company's stock valued at $2,304,000 after acquiring an additional 1,337 shares during the period. Finally, SMART Wealth LLC bought a new stake in shares of ADMA Biologics in the fourth quarter valued at about $208,000. Institutional investors own 75.68% of the company's stock.

ADMA Biologics Stock Down 1.9%

ADMA stock opened at $19.94 on Friday. The company has a market cap of $4.76 billion, a PE ratio of 71.21 and a beta of 0.57. The business has a 50-day simple moving average of $20.67 and a 200 day simple moving average of $18.88. ADMA Biologics, Inc. has a 52 week low of $10.08 and a 52 week high of $25.67. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). The company had revenue of $114.80 million during the quarter, compared to analyst estimates of $116.40 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The firm's revenue for the quarter was up 40.2% compared to the same quarter last year. During the same period last year, the firm earned $0.08 EPS. Sell-side analysts anticipate that ADMA Biologics, Inc. will post 0.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen cut shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $25.00 price target on shares of ADMA Biologics in a research note on Tuesday, March 4th. Finally, Raymond James boosted their price target on ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research note on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $24.25.

Insiders Place Their Bets

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 7,779 shares of the business's stock in a transaction dated Wednesday, May 21st. The stock was sold at an average price of $20.32, for a total transaction of $158,069.28. Following the completion of the transaction, the director now owns 114,830 shares of the company's stock, valued at approximately $2,333,345.60. The trade was a 6.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 3.50% of the company's stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.